E-viri
Recenzirano
Odprti dostop
-
Lincoff, A. Michael; Brown-Frandsen, Kirstine; Colhoun, Helen M.; Deanfield, John; Emerson, Scott S.; Esbjerg, Sille; Hardt-Lindberg, Søren; Hovingh, G. Kees; Kahn, Steven E.; Kushner, Robert F.; Lingvay, Ildiko; Oral, Tugce K.; Michelsen, Marie M.; Plutzky, Jorge; Tornøe, Christoffer W.; Ryan, Donna H.
The New England journal of medicine, 12/2023, Letnik: 389, Številka: 24Journal Article
In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.
